|
A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
RECRUITINGPhase 3Sponsored by Novo Nordisk A/S
Actively Recruiting
PhasePhase 3
SponsorNovo Nordisk A/S
Started2026-09-22
Est. completion2028-10-10
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations45 sites
View on ClinicalTrials.gov →
NCT07668414
Summary
The purpose of this study is to find out if zenagamtide is safe and effective for treating participants who have excess body weight compared to treatment with semaglutide.
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: * Male or female (sex at birth). * Age 18 years or above at the time of signing the informed consent. Exclusion Criteria: * Glycated haemoglobin (HbA1c) ≥ 6.5% (48 millimoles per mole \[mmol/mol\]) as measured by the central laboratory at screening. * History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records. * Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues within 1 year before screening.
Conditions3
ObesityOverweightWeight Loss
Interventions4
Locations45 sites
First Valley Medical Group
Desert Oasis Healthcare
Western University of Health Sciences
Artemis Insitute for Clin Res
Med Home Development Grp
Find trials near these locations
Weight Loss trials in San DiegoWeight Loss trials in JacksonvilleWeight Loss trials in MiamiWeight Loss trials in OrlandoWeight Loss trials in AtlantaWeight Loss trials in ChicagoWeight Loss trials in IndianapolisWeight Loss trials in AustinWeight Loss trials in DallasWeight Loss trials in HoustonWeight Loss trials in San AntonioWeight Loss trials in SeattleAll trials in CaliforniaAll trials in District of ColumbiaAll trials in FloridaAll trials in GeorgiaAll trials in IllinoisAll trials in IndianaAll trials in LouisianaAll trials in MissouriAll trials in New YorkAll trials in North CarolinaAll trials in North DakotaAll trials in PennsylvaniaAll trials in South CarolinaAll trials in TexasAll trials in VirginiaAll trials in Washington
Related trials
- A Research Study Looking at Kidney and Heart Health in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in China — Novo Nordisk A/S
- A Study of BGM0504 in Early T2DM With Obesity — BrightGene Bio-Medical Technology Co., Ltd.
- A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2) — Actimed Therapeutics Ltd
- COMMETS- Combination MCI Metabolic Syndrome — Rutgers, The State University of New Jersey
- GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM — Federico II University
- Lean Mass Changes With Semaglutide in Adults With Type 1 Diabetes and Overweight/Obesity. — McGill University Health Centre/Research Institute of the McGill University Health Centre
- Mechanisms of Weight Loss: Tirzepatide vs Semaglutide — McMaster University
- Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes — Steno Diabetes Center Copenhagen
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 3
SponsorNovo Nordisk A/S
Started2026-09-22
Est. completion2028-10-10
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations45 sites
View on ClinicalTrials.gov →
NCT07668414